



**Addendum:** Statement on nutritional supplements and piracetam for children with Down syndrome

Manisha Balwani, MD for the American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee

*Genetics in Medicine* (2020) 22:2127; <https://doi.org/10.1038/s41436-020-0847-9>

The original statement was published in the ACMG newsletter in 1996.

This document was retired by the ACMG Board of Directors as of 27 April 2020 with the following addendum:

Based on the current literature,<sup>1,2</sup> the use of piracetam or other nutritional supplements in the health supervision for children with Down syndrome is not recommended.

## REFERENCES

1. Lobaugh NJ, Karaskov V, Rombaugh V, et al. Piracetam therapy does not enhance cognitive functioning in children with Down syndrome. *Arch Pediatr Adolesc Med.* 2001;155:442–448.
2. Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. *Pediatrics.* 2011;128:393–406. Reaffirmed in *Pediatrics.* 2018;141:e20180518.

---

Correspondence: ACMG ([documents@acmg.net](mailto:documents@acmg.net))

Submitted 14 May 2020; accepted: 14 May 2020  
Published online: 8 June 2020